Brief: Lipocine to change FDA labeling for testosterone products
12/03/2025 13:59
March 12 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE ANNOUNCES FDA LABELING CHANGES FOR TESTOSTERONE PRODUCTS LIPOCINE: FDA RECOMMENDED BOXED WARNING RELATED TO INCREASED RISK OF ADVERSE CARDIOVASCULAR OUTCOMES BE REMOVED FROM LABELS OF TESTOSTERONE PRODUCTS LIPOCINE: FDA IS ALSO REQUIRING ALL LABELS TO INCLUDE PRODUCT-SPECIFIC INFORMATION ON INCREASED BLOOD PRESSURE FOR TESTOSTERONE PRODUCTS Source text: ID:nPn85YV8Pa Further company coverage: LPCN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy